China-based but NASDAQ-listed Bon Natural Life Limited (BON), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, has recently launched a new cruciferous vegetable based probiotic powder drink that could potentially inhibit the proliferation of Helicobacter pylori and help regulate the digestive system. The powder drink is the first proprietary product of BON’s cruciferous vegetable based health supplement series.
Yongwei Hu, CEO and Chairman of BON said, “We believe that the successful rollout of this new powder drink will provide an additional growth driver for BON and capitalise the increasing awareness and consumption of multifunctional probiotics both during and post COVID-19 pandemic. We are confident that the new nutraceutical series will enable us to enter into a whole new era of growth.
H. pylori infection has become a major global health problem. According to research by, approximately 55.8% of the Chinese population were infected with H. pylori in 2017, which provides BON with a huge market potential for its broccoli sprout based probiotic powder drink.
According to Euromonitor, the market size of probiotics increased by 173.9% from US$7.3 billion in 2015 to about US$12.7 billion in 2020 in China, with a CAGR of 11.83%. China has become the 3rd largest probiotics market after the US and Italy.
By formulating 3 different kinds of patented probiotics with sulforaphane, a chemical compound extracted from broccoli, and fucoidan, a compound extracted from seaweed, BON is able to leverage its innovative technology to develop a product with potential anti-pylori effect. Additionally, this powder drink could also regulate and improve one’s overall microbiome and digestive health.
H. pylori is a bacterial pathogen that infects over 50% of the world population. It has been identified as a Group I carcinogen by WHO. H. pylori infection could be a precursor to gastric cancer, peptic ulcer disease, and mucosa-associated lymphoid tissue (MALT) lymphoma. The eradication rate of H. pylori in recent years has been difficult, mainly due to high resistance of H. pylori to antibiotics which are commonly used in standard treatment.
